No Data
No Data
Amgen (AMGN.US) and Astrazeneca (AZN.US) received breakthrough therapy designation from the FDA for their first-in-class therapy for treating COPD.
Two companies are planning to launch phase III clinical trials in COPD patients.
Despite Lower Earnings Than Five Years Ago, Amgen (NASDAQ:AMGN) Investors Are up 83% Since Then
Why It Might Not Make Sense To Buy Amgen Inc. (NASDAQ:AMGN) For Its Upcoming Dividend
What Eli Lilly, Novo Nordisk Earnings Reveal About the Future of GLP-1 Sales
About 73% of the S&P 500 Names Beat on EPS During the Week - Earnings Scorecard
Notable Analyst Calls This Week: Disney, Super Micro and Amgen Among Top Picks